Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $66.00

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given an average recommendation of “Moderate Buy” by the five analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $66.00.

Several brokerages recently commented on CLDX. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research note on Friday, March 22nd. Finally, Guggenheim lifted their price target on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th.

Celldex Therapeutics Trading Down 1.4 %

Shares of CLDX opened at $37.98 on Wednesday. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18. The firm’s fifty day simple moving average is $42.03 and its 200-day simple moving average is $35.80. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -13.05 and a beta of 1.49.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The firm had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million. On average, analysts predict that Celldex Therapeutics will post -2.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Hong Kong Ltd grew its position in Celldex Therapeutics by 57.9% during the 1st quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 511 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Celldex Therapeutics by 70.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 805 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Celldex Therapeutics by 604.9% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,178 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 1,869 shares during the last quarter. Strs Ohio grew its position in Celldex Therapeutics by 92.9% during the 4th quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in Celldex Therapeutics by 78.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 2,782 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 1,226 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.